-Dow Jones
Regeneron’s Evkeeza Under FDA Priority Review For Younger Kids With Inherited Form Of High Cholesterol
The FDA has accepted Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) supplemental marketing application seeking approval for Evkeeza (evinacumab-dgnb) as an adjunct to other…